Cannnabidiol-carbonsaeure-(3') | 1244-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cannnabidiol-carbonsaeure-(3')
• 英文别名: 2,4-dihydroxy-3-[(1R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid
• CAS: 1244-58-2；19206-65-6
• 化学式: C₂₂H₃₀O₄
• 分子量: 358.478
• InChiKey: WVOLTBSCXRRQFR-ZYMOGRSISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] CANNABINOID DERIVATIVES<br/>[FR] DÉRIVÉS CANNABINOÏDES
  申请人：CANOPY GROWTH CORP

  公开号：WO2021000054A1

  公开（公告）日：2021-01-07

  The present disclosure relates to a carmabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a carmabinoid receptor in a subject in need thereof, such as acute pain, ADHD/ ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, etc. The carmabinoid derivative has the following formula:

  本公开涉及一种卡马比诺衍生物，包括它的药物组合物，以及其在治疗和预防与受试者中需要的卡马比诺受体相关的疾病，如急性疼痛、ADHD/ADD、酒精使用障碍、过敏性哮喘、肌萎缩侧索硬化症、阿尔茨海默病、厌食症等方面的用途。该卡马比诺衍生物具有以下结构式：
• Enhanced smokable therapeutic cannabis product and method for making same
  申请人：NC3 Systems

  公开号：US10172897B2

  公开（公告）日：2019-01-08

  An enhanced smokable cannabis-based product produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, enriching the extracted oil with a formulation comprising at least purified-myrcene, and spraying the enriched oil onto dried smokable cannabis plant matter.

  一种通过以下方法生产的增强型可吸食大麻产品：从大麻植物材料中分离出大麻脂，压榨大麻脂以排出油，留下废大麻脂，使用 MCT 油从废大麻脂中进一步提取大麻素，用至少包含纯化月桂烯的配方富集提取的油，以及将富集的油喷洒到干燥的可吸食大麻植物物质上。
• NOVEL CANNABIDIOL QUINONE DERIVATIVES
  申请人：Emerald Health Pharmaceuticals Inc.

  公开号：EP3131874B1

  公开（公告）日：2018-07-25
• USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS
  申请人：Hava David L.

  公开号：US20130203715A1

  公开（公告）日：2013-08-08

  Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.
• CANNABIS-BASED THERAPEUTIC PRODUCT FOR TREATMENT OF CHRONIC PAIN
  申请人：CMG PARTNERS, INC.

  公开号：US20190224142A1

  公开（公告）日：2019-07-25

  A cannabis-based therapeutic product for treatment of chronic pain produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, separating the cannabis compounds from the oils using high pressure liquid chromatography, flash chromatography, or similar techniques, and processing selected cannabis compound formulations into a form suitable for administration as a therapeutic product for treatment of chronic pain. The therapeutic product has at least 28% w/w cannabinol (CBD), and at least 2% w/w β-myrcene.